Ayala Pharmaceuticals (NASDAQ:ADXS) Earns Sell Rating from Analysts at StockNews.com

Ayala Pharmaceuticals logoStockNews.com initiated coverage on shares of Ayala Pharmaceuticals (NASDAQ:ADXS – Get Rating) in a research note issued to investors on Saturday. The firm sets a “sell” rating on the stock.

Ayala Pharmaceuticals Trading Down 4.0 %

ADXS stock opened at $0.72 on Friday. The stock has a market capitalization of $1.31 million, a price-to-earnings ratio of -0.08 and a beta of 2.44. Ayala Pharmaceuticals has a 1 year low of $0.65 and a 1 year high of $7.20.

About Ayala Pharmaceuticals

(Get Rating)

Want More Great Investment Ideas?

Advaxis, Inc. is a biotechnology company, which engages in the discovery, development and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. The firm has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy and hotspot mutation therapy.

Featured Stories

Receive News & Ratings for Ayala Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Ayala Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.